- Two new appointments follow oversubscribed $75 million (€64 million) Series B financing and support next stage of iTeos’ growth
Gosselies, Belgium – June 27, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the appointment of David Hallal, former Chief Executive Officer of Alexion Pharmaceuticals, and Tim Van Hauwermeiren, Chief Executive Officer of argenx, to its board of directors. David has been appointed Chairman and Tim joins as an independent non-executive director.
“David and Tim are both extremely well regarded executives and we are thrilled to have them join the iTeos Board at this stage in our growth. Their combined commercial experience running large biotechnology companies will be invaluable as we advance our innovative next-generation immuno-oncology pipeline and expand our presence in the U.S.,” said Michel Detheux, Ph.D., Chief Executive Officer of iTeos. “Our recent financing and diversified Board put us in an even stronger position to rapidly move our promising therapies into the clinic and to design additional therapeutic candidates based on our industry-leading drug discovery and early clinical development expertise.”
David Hallal brings nearly 30 years of senior executive leadership experience in growing and operating several of the world’s most successful biotechnology companies. David spent more than 10 years at Alexion Pharmaceuticals as Chief Executive Officer, Chief Operating Officer and Chief Commercial Officer and played a central role in transforming the company from a development-stage company in 2006 to a commercial-stage company operating in more than 50 countries with three approved products and more than $3 billion in annual revenues by 2016. Prior to Alexion, David held leadership positions at Amgen, Biogen and Eyetech. He also serves as Chairman of Scholar Rock (Nasdaq: SRRK).
Tim Van Hauwermeiren is currently Chief Executive Officer of argenx (Euronext & Nasdaq: ARGX), which he co-founded in 2008 and where he has also served on the Board since July 2014. At argenx, Tim has created a multi-billion-dollar enterprise with three therapies in mid- to late-stage development. Tim has more than 20 years of general management and business development experience across the life sciences and consumer goods sectors. Previously, he held senior leadership roles at Ablynx and Procter & Gamble.
“It’s an exciting time of growth and expansion at iTeos as it prepares to transition its highly differentiated adenosine A2A receptor antagonistinto the clinic, and I am delighted to join the Board as Chairman,” said David Hallal. “Together with Michel, Tim and the other Board members, I will be focused on executing the Company’s strategy to develop innovative therapies that can transform the lives of patients suffering with cancer.”
“iTeos is proving to be a key player in the emerging cancer immunotherapy space and I am very much looking forward to working with the team to progress iTeos’ pipeline and provide guidance to help the Company realize its full potential,” added Tim Van Hauwermeiren.
iTeos’ Board of Directors now consists of David Hallal (Chairman); Ansbert Gadicke, M.D.; Christiana Bardon M.D. MBA; Priyanka Belawat, Ph.D.; Tim Van Hauwermeiren, MSc, EMBA; Chris Buyse, MBA, Jonathan Skipper, Ph.D. and Michel Detheux, Ph.D. (CEO).
About iTeos Therapeutics
iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed an oversubscribed $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All previous investors including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round.For more information, please visit www.iteostherapeutics.com.
For further information, please contact:
Michel Detheux, CEO
Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys
Consilium Strategic Communications
+44 203 709 5700
Stern Investor Relations, Inc.
+ 1 212 362 1200
iTeos Therapeutics SA, a drug discovery company focused on the development of immunomodulators for cancer therapy, today announced the successful closing of its Series A equity financing round. iTeos, a joint spin-off of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute at the Université catholique de Louvain (UCL), raised €3.0 million from LICR, Hunza Ventures SCA, Life Sciences Research Partners, VIVES Louvain Technology Fund and several business angels. This financing complements a €6 million non-dilutive grant from the Belgian Walloon Government, which was received in December 2011. Cancer immunotherapy has gained momentum in the two last years because of the clinical success of new immunotherapeutic treatments. Immunotherapy can harness the immune system to selectively destroy tumors and limit the risk of recurrences, with very limited side effects. However, the success of cancer immunotherapy has been limited by the ability of tumors to block the immune response, something known as immunosuppression. Scientists are now working to better understand the mechanisms responsible for immunosuppression, in order to devise strategies to overcome them. This is what iTeos’ research program strives to do: develop small-molecule immunomodulators that can increase the efficacy of cancer immunotherapy, as well as leverage the spontaneous anti-tumor immune response. “We believe that the efficacy of most cancer therapies — not only immunotherapy — will be greatly enhanced by the control of tumor immunosuppressive mechanisms,” said Benoît Van den Eynde, Brussels Branch Director at LICR, UCL Professor and co-founder of iTeos. “Our first strategy will aim to combine existing vaccines with new immunomodulators based on technology that was licensed from LICR. Thereafter we will explore combinations with other cancer therapies,” added Van den Eynde. “iTeos brings together the world-class expertise of LICR in immunotherapy and tumor immunology with a team of drug discovery experts to develop innovative treatments against severe diseases such as lung, pancreatic and liver cancers,” said iTeos co-founder and CEO Michel Detheux. “With substantial funding now in place, iTeos is well-positioned to execute its ambitious strategy over the next several years by accelerating the clinical development of its flagship program, as well as two additional preclinical programs,” added Detheux. “Moving early-stage research advances from LICR scientists into later-stage clinical testing for the benefit of patients is a priority for the Institute,” said Jonathan Skipper, Executive Director of Technology Development at LICR. “iTeos will have access to LICR’s expertise and infrastructure so that candidate therapeutics can be rapidly tested,” added Skipper. “We are very proud to establish a joint spin-off company between two prestigious institutes — LICR and the de Duve Institute at UCL. iTeos combines a solid pipeline with the expertise to develop a new discovery platform in immunomodulation," concluded Philippe Durieux, CEO of SOPARTEC and managing director of VIVES Louvain Technology Fund. The iTeos Board is comprised of industrial, scientific and financial experts, including Philippe Guinot as independent Chairman, Natacha Beaumont (Managing Director, Hunza Ventures), Chris Buyse (CFO, ThromboGenics), Philippe Durieux (VIVES) and Jonathan Skipper (Executive Director of Technology Development, LICR). The Scientific Committee comprises Jean-Yves Bonnefoy (VP R&D, Transgene), Pierre Coulie (UCL) and Douglas Fearon (Cambridge University). Eubelius was the legal advisor of the company in this transaction. All parties involved decided not to disclose any further financial information regarding this transaction. For more information, please visit www.iteostherapeutics.com or contact Michel Detheux at +32478034600, or by email at email@example.com. About iTeos Therapeutics SA Based in Gosselies, Belgium, iTeos Therapeutics SA is a private biotechnology company with a focus on developing small-molecule immunomodulators for cancer treatment. Originating from a partnership between the Ludwig Institute for Cancer Research and de Duve Institute at the Université catholique de Louvain, iTeos Therapeutics SA is led by management and research teams with proven track records in tumor immunology, immunotherapy, drug discovery and development. About Ludwig Institute for Cancer Research (LICR) LICR is an international non-profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for patient benefit. Since its establishment in 1971, the Institute has expended more than $1.5 billion on cancer research. For more information, please visit www.licr.org. About Life Sciences Research Partners Life Sciences Research Partners (formerly called D Collen Research Foundation) was founded by Emeritus Professor Désiré Collen in 1988. The purpose of Life Sciences Research Partners is, without any profit-making intentions, to carry out, promote and support scientific research in general and biomedical and biotechnological research in particular. The specific activities by which the purposes of the association will be realized are among others the awarding of research grants, research mandates and traveling scholarships, the organization of scientific congresses and symposia, financial support of publications, and any other related activities that support or help to propagate the advancement of science. In addition, the association may conduct any other activity, that contributes directly or indirectly to its non-profit purpose, including commercial and profitable activities within legal boundaries, on condition that the profit thereof be exclusively spent on the non-profit purposes of the association. For more information, please visit www.lsrp.be. About VIVES-Louvain Technology Fund VIVES-Louvain Technology Fund is a multi-sectorial technology investment fund that invests in spin-offs ofUniversité catholique de Louvain (UCL) as well as start-ups in Belgium and neighboring countries. The objective of the fund is to invest in the development of start-ups, from technological validation through to commercial maturity. The funds (VIVES 1 of EUR 15 mio and VIVES 2 of EUR 43mio) are managed by SOPARTEC, the technology transfer company of the Université catholique de Louvain (UCL). Through Louvain Technology Transfer Office (LTTO), SOPARTEC and the University´s Research Administration (ADRE) are in charge of the overall technology transfer process. This covers the financing of research contracts, the identification of inventions within the laboratories, the protection and management of intellectual property,the technological maturation and the commercialization (through licensing and/or spin-off). More specifically, SOPARTEC coordinates the management of licensing agreements and the technological maturation of UCL spin-offs. More than 50 spin-offs, which today generate more than 3,000 jobs, have been created in whole or part from the results of research conducted at the UCL. These include Ion Beam Application (IBA), I.R.I.S. Group, IbT, Telemis, Alterface, Cissoid, Viridaxis, Promethera, Greenwatt, etc. For more information, please visit http://www.vivesfund.com. About Hunza Ventures SCA Hunza Ventures is a venture capital firm dedicated to the life sciences and information technology currently managing in excess of €20 million. Founded in 1998, Hunza Ventures has built a balanced portfolio of companies developing novel approaches and best-in-class products. With its strong sector expertise and through its multidisciplinary team and entrepreneurial approach, the fund prides itself in truly partnering with its portfolio companies. For more information, please visit www.hunza-ventures.com. About UCL Founded in 1425, one of Europe’s oldest universities, UCL has 27,289 students on six sites (Louvain-la-Neuve, Bruxelles (Woluwe and Saint-Gilles), Mons, Tournai, Charleroi). UCL educates almost one in every two French-speaking Belgians, and attracts every year 4,000 international students from around the globe (a number of programmes are given in English). UCL trains students in all disciplines, from beginner’s level through doctorate level and on to adult continuing education. Teaching is based on solid research and innovation. UCL is also one of the 22 European Universities to have received the ECTS label, a European Union recognition of the quality of its management of international exchanges. In the latest QS World University Rankings (2011), UCL was located at the 125e position, which makes it the first French speaking university of Belgium. For more information, please visit www.uclouvain.be. About de Duve Institute Founded in 1974 by Nobel Prize Laureate Christian de Duve, the de Duve Institute is a renowned multidisciplinary biomedical research institute located on the Brussels campus of the Université catholique de Louvain (UCL), next to the Cliniques Universitaires Saint-Luc. It hosts several laboratories of the Faculty of Medicine of UCL, as well as the Brussels Branch of the Ludwig Institute for Cancer Research. Research priorities at the de Duve Institute are based on three principles: (i) priority to fundamental research and to the freedom of the investigators, (ii) special attention to medical benefits potentially resulting from fundamental discoveries (iii) multidisciplinary collaboration within a critical mass of competences. For more information, please visit www.deduveinstitute.be.
Gosselies, Belgium and Cambridge, MA – September 9th, 2019 – iTeos Therapeutics SA (iTeos), a privately-held biotechnology company developing novel cancer immunotherapies, today announced that it has added four new world-leading experts in oncology, immunology, and drug discovery and development to its Scientific Advisory Board (SAB): Gordon Freeman, William Hahn, Ben Stanger and Matt Vander Heiden. The SAB will support the development of iTeos’ pipeline of clinical and preclinical assets targeting key mechanisms of immunosuppression, in order to transform the lives of people living with cancer. The full SAB comprises: Gordon Freeman, Ph.D, Researcher at Boston’s Dana-Farber Cancer Institute, who will become Chairman of the SAB William C. Hahn, M.D.,Ph.D, Chief Research Strategy Officer at Boston’s Dana-Farber Cancer Institute Ben Z. Stanger, M.D, Professor in Cancer Research at the University of Pennsylvania’s Perelman School of Medicine Matthew G. Vander Heiden, Ph.D., Associate Director at the Massachusetts Institute of Technology’s (MIT) Koch Institute for Integrative Cancer Research Benoit Van den Eynde M.D., Ph.D, Director of the Brussels Branch of the Ludwig Institute for Cancer Research, Ltd. and co-founder of iTeos and previously Chairman of the SAB, will remain a key member of the SAB Pierre Coulie, M.D., Ph.D. Professor of Immunology, the De Duve Institute of the Université Catholique de Louvain Scott Chappel, Ph.D. Chief Scientific Officer at iTeos Therapeutics Michel Detheux, Ph.D., Chief Executive Officer of iTeos, commented: “By assembling this new Scientific Advisory Board, iTeos gains access to a broad range of expertise and extensive knowledge. As we advance our highly-differentiated pipeline of immunotherapies that target the tumor microenvironment, with the aim of enhancing the anti-tumor immune response and addressing some of the limitations of first-generation immunotherapies, their scientific rigour will be invaluable. “While welcoming the new members of the SAB, I would also like to thank the retiring members including Dr. Jean-Yves Bonnefoy, Prof. Vincenzo Bronte, Prof. Vincenzo Cerundolo, Prof. Douglas Fearon, Dr. Jedd Wolchok and Dr. Thomas Gajewski. Their expertise and guidance have been integral to the growth of iTeos Therapeutics and I wish them all well in their future endeavours.” Gordon Freeman, Chairman of the Scientific Advisory Board of iTeos, commented: “I am delighted to be working with, and chairing, the Scientific Advisory Board at iTeos Therapeutics, an exciting company that I have been aware of for a long time and have followed their progress. iTeos’ pipeline of highly selective and potent drug candidates is one that includes some of the most promising drug candidates targeting the A2A pathway as well as TIGIT, a second-generation immune checkpoint inhibitor that is gaining increased interest from big pharma and will enter the clinic in the second half of 2019. I look forward to advising the team through the next stages of their clinical development.” Additional background on all SAB members can be found on the iTeos website. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics firstname.lastname@example.org Amber Fennell, Mathew Neal, Sukaina Virji, and Catherine London (US) Consilium Strategic Communications +44 203 709 5700 email@example.com Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com
Gosselies, Belgium and Cambridge, MA – 13 August, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announces the appointment of Matthew Call as its Chief Operating Officer. Matthew will also be responsible for business development. Matthew joins iTeos with 20 years of experience in operational leadership and business development roles, most recently serving as Chief Operating Officer at Endocyte, which was acquired by Novartis for $2.1 billion in 2018. During his 16 year tenure at Endocyte, he had responsibility for all business development and strategic transactions and led a variety of functions including new product planning, marketing and project management. “At iTeos we have built an experienced team that has been hand-picked from across industry to accelerate our efforts of bringing the next generation of immuno-oncology therapies to patients. Matt’s extensive business development background, corporate strategy experience and operational track record is precisely what we need at this stage of our growth and he will be an integral addition to iTeos and the growing executive team,” said Michel Detheux, Ph.D., co-founder, President and Chief Executive Officer of iTeos. “We look forward to his strategic and operational leadership as we advance our pipeline of highly-differentiated immunotherapies through the clinic and we continue to grow our organization.” “I am delighted to join iTeos at such an exciting time as the company advances its key growth initiatives. Our talented staff, highly differentiated pipeline programs, and strong investor base positions iTeos well to transform the treatment paradigm for people living with cancer,” said Matthew Call, Chief Operating Officer of iTeos. About iTeos Therapeutics iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is an adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics firstname.lastname@example.org Amber Fennell, Mathew Neal, Sukaina Virji, and Catherine London Consilium Strategic Communications +44 203 709 5700 email@example.com Sarah McCabe Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com